A cost-effectiveness analysis of trastuzumab plus docetaxel vs. docetaxel alone for the treatment of HER2-positive metastatic breast cancer in the Greek healthcare setting

Athanasakis K, Kyriopoulos J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Antibodies, Monoclonal, Humanized; Taxoids; Breast Neoplasms; Receptor, ErbB-2; Greece

AccessionNumber
22013016995

Date bibliographic record published
30/05/2013